Status:
ACTIVE_NOT_RECRUITING
Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
Foundation for Anesthesia Education and Research
Conditions:
Neuropathy;Peripheral
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To learn if a process called neuromodulation can help to improve pain due to CIP
Detailed Description
Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document * Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bort...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Ability to understand and the willingness to sign a written informed consent document
- Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds
- Patients seen at Pain Management Center at MD Anderson Cancer Center
- Patient ages greater or equal to 18 years but less than or equal to 85 years
- Exclusion Criteria
- Patients with cognitive dysfunction
- Patient with recent history (\<6 months) of drug or alcohol abuse
- Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection
- Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy
Exclusion
Key Trial Info
Start Date :
November 2 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06121232
Start Date
November 2 2023
End Date
April 1 2026
Last Update
November 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030